Description
This product utilizes CD4+ T cells that have been engineered with our proprietary GeneCircuit technology to specifically target CD22 ( clone IRO23). We employs the Lentivirus (trc-Cy2-GR-SaII) vector components and the SynExpress system of the exons Inversion/Positive feedback for a robust and sustained response against cancers.
Host
Humanized
Target
CD22
Clone
IRO23
Species Reactivity
Human
Cell Source
Synthetic CD4+ T cells
Sensor Gene
Cy2
Promoter
trc
Effector Gene
GR
Insertion Sites
SaII
Gene Modification
Inversion
Modification Domain
Exons
Carrier Type
Lentivirus
Transformation Accuracy
0.99
Cell Culture
Microcarrier Culture

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2025 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.